Latest Deals
Credit: SewCreamStudio / Shutterstock
Lilly partners with Haya for lncRNA obesity target deal worth $1bn
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity.Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
ArsenalBio secures $325m to develop cell therapy programmes
ArsenalBio has closed an oversubscribed Series C financing round, securing $325m to propel its programmable cell therapy programmes through clinical development. The funds will support the advancement of the company’s lead programmes and innovation in cell therapy tools and processes. This financing round attracted new investors including ARCH Venture Partners, Luma Group, Milky Way Investments Group, NVentures and Regeneron Ventures.
eGenesis scoops $191m for genetically modified pig kidney transplant trial
Investors are rallying around the promise of cross-species transplantation, enabling eGenesis to close a $191m Series D financing round to advance its genetically engineered porcine kidney organ. The US biotech said the funds will advance its candidate – called EGEN-2784 – to a first-in-human study, push its pipeline, and scale production, according to a 4 September press release.
Nxera wins $35m after Phase II schizophrenia trial success
Japanese biopharma Nxera Pharma has secured $35m in milestone payments from Neurocrine Biosciences following positive Phase II trial data of NBI-1117568 (NBI-568) in adults with schizophrenia. Neurocrine reported positive data from the Phase II dose-finding study last week, highlighting that the study met its primary endpoint with a significant reduction in schizophrenia symptoms at a once-daily 20mg dose.
